Insight certainty 4/5 debate potential 2/5

Garfinkel: Device Reimbursement Path Adds up to $50M in Development Costs

Jan Garfinkel · Jan Garfinkle – Arboretum Ventures (Manager Meetings, EP.09) · Sep 2, 2021 · at 57:16

Jan Garfinkel, founder of Arboretum Ventures, explains the financial burden of obtaining CMS reimbursement approval for new medical devices beyond FDA clearance.

0:00 / 0:12exact quote · 12.0s
720p mp4 · rendered on demand · StarZero watermark
“If we have to also go through the reimbursement path, it will add another up to fifty million dollars to that company's development and timeline, but cost to develop that product to get reimbursement approval.”

quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →

More from Jan Garfinkel

Insight
Garfinkel: Midwest Startups Cost 33% Less to Build, Adding 1x Return
“The beauty of being in the Midwest and focusing primarily on Midwestern companies is that it takes about a third less dollars to develop the company in the Midwest because salaries, rent, vendor costs, just all those things all combined. You basically get an a…”
Jan Garfinkel Sep 2, 2021 ▶ 33:38 Jan Garfinkle – Arboretum Ventures (Manager Meetings, EP.09)
Insight
Garfinkel: Pharma Adjacencies Capture Upside Without Binary Trial Failure Risk
“Pharma adjacencies, which is companies that play in the pharma space, but it's without a drug, so they have the same upside potential, because pharma has big upside potential, but without the binary risk that the drug would fail in phase three.”
Jan Garfinkel Sep 2, 2021 ▶ 45:02 Jan Garfinkle – Arboretum Ventures (Manager Meetings, EP.09)
Insight
Garfinkel: Venture Capital Skills Can Be Taught; Cultural Fit Cannot
“We feel we can teach anybody how to do venture, how we evaluate companies, how we help the board level. We can teach all of those things. We want to make sure they're a cultural fit from a personality standpoint and a work ethic.”
Jan Garfinkel Sep 2, 2021 ▶ 38:15 Jan Garfinkle – Arboretum Ventures (Manager Meetings, EP.09)
Assertion Not checkable as stated
Garfinkel: Half of Arboretum's 15 Major Exits Were Within One Mile
“I think we've invested now in 50 or 55 companies. We've had about 20 exits, but 15 that were in sort of the five to 10 X range, and when you look at that, half of them are a mile from our office.”
Jan Garfinkel Sep 2, 2021 ▶ 52:05 Jan Garfinkle – Arboretum Ventures (Manager Meetings, EP.09)
Insight
Garfinkel: Many Healthcare Startup Exits Occur Between $200M and $400M
“In the world we live in, in healthcare, many of the exits are in the 200 to four hundred million dollar range.”
Jan Garfinkel Sep 2, 2021 ▶ 33:06 Jan Garfinkle – Arboretum Ventures (Manager Meetings, EP.09)
Disclosure
Garfinkel: Hiring Pure Investment Bankers Did Not Work Well for Arboretum
“And when we've tried to bring in people that are just like bankers, that hasn't worked out nearly as well for us.”
Jan Garfinkel Sep 2, 2021 ▶ 35:03 Jan Garfinkle – Arboretum Ventures (Manager Meetings, EP.09)
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 700 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.